Monday, July 24, 2017

Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed …

March 13, 2015 by  
Filed under Depression

DUBLIN, March 13, 2015 /PRNewswire/ -- Actavis plc (ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). SAPHRIS is the only atypical antipsychotic treatment ...

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!